ILYPSA COMPLETES TRIAL OF ILY101

A A

Ilypsa has completed a Phase I clinical trial for ILY101, a novel phosphate-binding agent that is being developed for the treatment of hyperphosphatemia, a serious complication in patients with chronic kidney disease (CKD) on dialysis.

The study examined the safety and tolerability of single and multiple doses of orally-administered ILY101 in twenty-four healthy volunteers. With the successful completion of Phase I, the company expects to initiate a Phase II study in CKD patients on dialysis.